ProMIS Neurosciences Inc. Announces Upsize of Previously Announced Public Offering of Units to US$17.5M
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug….
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug….
CHICAGO, Aug. 18, 2021 (GLOBE NEWSWIRE) — Cosmos Holdings, Inc. (“the Company”) (OTCQX: COSM), an…
Expanded Facility Capacity Provides Additional Growth Working Capital Availability at Low Cost of Capital NEW…
GLOBAL CELL & GENE THERAPY SECTOR ON PACE FOR ANNUAL RECORDS IN PRODUCT APPROVALS AND…
Third Quarter Revenues Increased by 88% Compared to the Same Period Last Year LAS VEGAS,…
CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) — Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage…
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused…
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 18, 2021 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB),…
Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction, David Lasseter, and…
STRATHROY, Ontario, Aug. 18, 2021 (GLOBE NEWSWIRE) — Eve & Co Incorporated (“Eve & Co”,…
Agreement allowing work on numerous collaborative research initiatives in the coming years DENVER, Aug. 18,…
GOODMIND™ Psyence Group Announces the Commencement of Online Sales and Distribution of “GOODMIND” Products TORONTO…
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) — Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company…
Werewolf Therapeutics to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE molecule, in combination…
Back Forty 40s Package Back Forty 40s recyclable packaging, designed for sharing out of the…
Completed the regulatory process required to ship medical cannabis to Brazil with import permits issued…
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, Aug….
MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpoints Study data indicates clinically meaningful improvement…
– No dose-limiting toxicities (DLTs) or clinically relevant adverse events observed as of August 17…